Literature DB >> 10023675

Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105.

R Ferrier1, R Nougarede, S Doucet, B Kahn-Perles, J Imbert, D Mathieu-Mahul.   

Abstract

The LYL1 gene was first identified upon the molecular characterization of the t(7;9)(q35;p13) translocation associated with some human T-cell acute leukemias (T-ALLs). In adult tissues, LYL1 expression is restricted to hematopoietic cells with the notable exclusion of the T cell lineage. LYL1 encodes a basic helix-loop-helix (bHLH) protein highly related to TAL-1, whose activation is also associated with a high proportion of human T-ALLs. A yeast two-hybrid system was used to identify proteins that specifically interact with LYL1 and might mediate its activities. We found that p105, the precursor of NF-kappaB1 p50, was the major LYL1-interacting protein in this system. The association between LYL1 and p105 was confirmed both in vitro and in vivo in mammalian cells. Biochemical studies indicated that the interaction was mediated by the bHLH motif of LYL1 and the ankyrin-like motifs of p105. Ectopic expression of LYL1 in a human T cell line caused a significant decrease in NF-kappaB-dependent transcription, associated with a reduced level of NF-kappaB1 proteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023675     DOI: 10.1038/sj.onc.1202374

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

Review 2.  NFκB function and regulation in cutaneous T-cell lymphoma.

Authors:  Tzu-Pei Chang; Ivana Vancurova
Journal:  Am J Cancer Res       Date:  2013-11-01       Impact factor: 6.166

Review 3.  Crosstalk in NF-κB signaling pathways.

Authors:  Andrea Oeckinghaus; Matthew S Hayden; Sankar Ghosh
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

4.  Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection.

Authors:  Yea-Lih Lin; Clement Mettling; Pierre Portales; Jacques Reynes; Jacques Clot; Pierre Corbeau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

5.  RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members.

Authors:  H Y Jiang; Constantinos Petrovas; Gail E Sonenshein
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner.

Authors:  Anu K Moorthy; Olga V Savinova; Jessica Q Ho; Vivien Ya-Fan Wang; Don Vu; Gourisankar Ghosh
Journal:  EMBO J       Date:  2006-04-13       Impact factor: 11.598

7.  Specific NEMO mutations impair CD40-mediated c-Rel activation and B cell terminal differentiation.

Authors:  Ashish Jain; Chi A Ma; Eduardo Lopez-Granados; Gary Means; William Brady; Jordan S Orange; Shuying Liu; Steven Holland; Jonathan M J Derry
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

8.  Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation.

Authors:  Manabu Minami; Koichi Shimizu; Yoshihisa Okamoto; Eduardo Folco; Marco-Lopez Ilasaca; Mark W Feinberg; Masanori Aikawa; Peter Libby
Journal:  J Biol Chem       Date:  2008-02-12       Impact factor: 5.157

Review 9.  Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology.

Authors:  Sören Beinke; Steven C Ley
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

10.  Prognostic Significance of the Lymphoblastic Leukemia-Derived Sequence 1 (LYL1) GeneExpression in Egyptian Patients with AcuteMyeloid Leukemia.

Authors:  Nadia El-Menshawy; Doaa Shahin; Hayam Fathi Ghazi
Journal:  Turk J Haematol       Date:  2014-06-10       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.